Cantor Fitzgerald Believes BioDelivery (NASDAQ: BDSI) Still Has Room to Grow

Cantor Fitzgerald analyst Brandon Folkes reiterated a Buy rating on BioDelivery (BDSIResearch Report) today and set a price target of $8. The company’s shares closed yesterday at $4.73, close to its 52-week high of $4.95.

Folkes wrote:

“. We are reiterating our Overweight rating and increasing our 12-month price target to $8, from $5. Our price target increase is driven by upwards earnings revisions for Belbuca. We believe Belbuca peak sales could exceed $300MM, above the $200MM+ management has previously guided to. Belbuca is a product which has found itself at the right place at the right time. That said, we believe BDSI is an execution story, and given the strong execution of the BDSI team to date, we are confident the company can continue to execute and fully maximize the value of Belbuca. As BDSI continues to execute we would expect further upwards earnings revisions to drive the stock higher.”

According to, Folkes is a 3-star analyst with an average return of 2.9% and a 46.8% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.

Currently, the analyst consensus on BioDelivery is a Moderate Buy with an average price target of $6.50.

See today’s analyst top recommended stocks >>

Based on BioDelivery’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.38 million. In comparison, last year the company had a GAAP net loss of $16.21 million.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction.